A Phase 3 interventional study of somatropin in Growth Hormone Disorder, Growth Hormone Deficiency in Children and Growth Disorder, sponsored by Novo Nordisk A/S. Completed at 40 sites in United States. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Growth Disorders with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Growth Disorders · United States.
Among the 25 studies in Growth Disorders with a site in United States, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2000, is one of 4 in phase 3, and was the 7th registered.
227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.
Browse Growth Disorders studies →4 of the 25 studies in Growth Disorders with a site in United States are open now. Recruiting first, the newest first:
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Northwell Health · Sites in United States
Ages 5–15 · Healthy volunteers
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 3 mo–100 yrs
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 1 mo–99 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Growth Disorders studies recruiting now, 3 (17%) set no upper age limit and 13 (72%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 3 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 1983; this study’s year is marked. 1 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is below the median of 413 across 143 interventional studies indexed under Growth Disorders.
Median enrollment 50 across the 17 interventional studies, 933 across the 8 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 8 studies filed under Growth Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Growth Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in height standard deviation score
Time frame: 24 month
IGF-I
IGFBP-3
free IGF-I
The record gives a start of Aug 2000, a primary completion of May 2004 and a completion of May 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone